# US 2017/0319644 A1 · Manufacture of degarelix

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319644 A1
- Document ID: US20170319644A1
- Status: Published application
- Kind: A1
- Application number: 15/420,156
- Filed: 2017-01-31
- Published: 2017-11-09
- Earliest claimed: 2012-06-01
- Assignees: Ferring B.V.
- Applicants: Ferring B.V.
- Inventors: Grégoire Schwach; Anders Nilsson; Tine Elisabeth Gottschalk Bøving; Jon Holbech Rasmussen; Birgitta Mörnstam; Anders Tsirk; Ulf Annby; Jens Fomsgaard
- Web page: https://patentgrep.com/patent/US20170319644A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for producing a degarelix drug substance comprising:
a. purifying degarelix obtained by solid phase peptide synthesis to obtain a degarelix solution with a purity of at least 95%;
b. concentrating the degarelix solution to obtain aggregated degarelix;
c. deaggregating the aggregated degarelix with acetic acid to obtain deaggregated degarelix; and
d. lyophilizing the deaggregated degarelix to provide the degarelix drug substance.

### Claim 24 (depends on 23)

The method of claim 23, wherein the purity of the degarelix solution is determined by high performance liquid chromatography (HPLC).

### Claim 25 (depends on 23)

The method of claim 23, wherein concentrating the degarelix solution involves evaporating from the degarelix solution solvent.

### Claim 26 (depends on 23)

The method of claim 23, wherein the purity of the degarelix solution is at least 97.5%.

### Claim 27 (depends on 23)

The method of claim 23, wherein the deaggregated degarelix has an acetic acid concentration of 15 to 35% (v/v).

### Claim 28 (depends on 23)

The method of claim 23, wherein the deaggregated degarelix has a temperature of minus 5 (−5) to 30 degrees centigrade.

### Claim 29 (depends on 23)

The method of claim 23, wherein the deaggregated degarelix has a free base concentration of 10 to 35 g/l.

### Claim 30

A method for producing a degarelix drug substance comprising:
a. purifying degarelix to obtain a degarelix solution with a purity of at least 95%;
b. loading the degarelix solution onto a chromatographic column;
c. eluting degarelix from the column to provide eluted degarelix, wherein the acetic acid concentration is 27 to 37%;
d. lyophilizing the eluted degarelix to provide the degarelix drug substance.

### Claim 31 (depends on 30)

The method of claim 30, wherein the eluted degarelix is filtered prior to lyophilization.

### Claim 32 (depends on 30)

The method of claim 30, wherein the degarelix is obtained by liquid or solid phase peptide synthesis.

### Claim 33 (depends on 30)

The method of claim 30, wherein the purity of the degarelix solution is determined by high performance liquid chromatography (HPLC).

### Claim 34 (depends on 30)

The method of claim 30, wherein the purity of the degarelix solution is at least 97.5%.

### Claim 35 (depends on 30)

The method of claim 30, wherein the aggregated degarelix is deaggregated with acetic acid to form the deaggregated degarelix.

### Claim 36 (depends on 35)

The method of claim 35, wherein the deaggregated degarelix has an acetic acid concentration of 15 to 35% (v/v).

### Claim 37 (depends on 35)

The method of claim 35, wherein the deaggregated degarelix has a temperature of minus 5 (-5) to 30 degrees Centigrade.

### Claim 38 (depends on 30)

The method of claim 30, wherein the deaggregated degarelix has a free base concentration of 10 to 35 g/l.

### Claim 39

A method for producing a degarelix drug substance comprising:
a. purifying degarelix to obtain a degarelix solution with a purity of at least 95%;
b. adjusting an acetic acid concentration of the purified degarelix solution to 6 to 40% (w/w); and
c. spray-drying the degarelix solution to provide the degarelix drug substance.
